Who is sponsoring NCT03370016?

NCT03370016 is sponsored by Metro Health, Michigan.

What drugs are being tested in NCT03370016?

Interventions in NCT03370016: Amount of Pneumoperitoneum Pressure applied during RARP.

What condition does NCT03370016 study?

NCT03370016 studies Prostate Cancer.

Is NCT03370016 still recruiting?

NCT03370016 is currently completed. Last updated 12 October 2023.

Last reviewed 2023-10-12 · How we verify

NCT03370016

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of Low Pressure Pneumo in RARP

Completed NA Last updated 12 October 2023

What this trial tests

NA trial testing Amount of Pneumoperitoneum Pressure applied during RARP in Prostate Cancer in 222 participants. Completed in 30 June 2020.

Timeline

17 October 2017

Primary endpoint
10 March 2020

30 June 2020

Quick facts

Lead sponsor	Metro Health, Michigan
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	222
Start date	17 October 2017
Primary completion	10 March 2020
Estimated completion	30 June 2020
Sites	1 location across United States

Drugs / interventions tested

Amount of Pneumoperitoneum Pressure applied during RARP

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Metro Health, Michigan

Who can join

40 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (RARP).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Metro Health, Michigan trials

Trials by the same sponsor.

NCT04394676 — The Impact of Low Pressure Pneumo in RARP II · NA · unknown
NCT03133312 — Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03370016 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Metro Health, Michigan
Last refreshed: 12 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03370016.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing